
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma Inc. reported a strong cash position with cash, cash equivalents, and marketable securities totaling $320 million, reflecting a positive increase primarily due to a recent private placement. The company’s focus on solid tumors through innovative T-cell reprogramming technologies, combined with encouraging data from its product candidates like LYL797 and LYL273, suggests a significant growth opportunity in the CAR-T market and beyond. While challenges such as potential dilution and the need for stronger efficacy data remain, the overall financial health and emerging data support a favorable outlook for future advancements in their clinical pipeline.
Bears say
Lyell Immunopharma experienced a decrease in research and development expenses, dropping from $34.9 million in the second quarter to $28.2 million in the third quarter of 2025. Despite this reduction, the company lacks sufficient evidence to demonstrate the durability of its treatments and the effective management of toxicity, which raises concerns regarding their clinical viability. The limitations in sample size and follow-up for LYL273 hinder a reliable assessment of its durability and toxicity mitigation, contributing to an overall negative outlook on the company’s prospects.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares